ViiV Healthcare’s Triumeq PD Receives the US FDA’s Approval as First Dispersible Single Tablet Regimen of Abacavir/Dolutegravir/Lamivudine for Children with HIV
Shots:
- The US FDA has approved NDA for Triumeq PD, a dispersible single-tablet regimen of the fixed-dose combination of abacavir, dolutegravir & lamivudine in children with HIV weighing 10kgs to <25 kgs
- Additionally, the US FDA has approved the sNDA to expand the use of Triumeq to lower the minimum weight of the children from 25kg to 40kg
- The MAA of Triumeq is currently under EMA’s review. Under the pediatric voluntary licenses, the company provides the generic versions of dolutegravir to manufacture and sold royalty-free for HIV patients in all least-developed, lower-middle-income, and sub-Saharan African countries along with upper-middle-income countries
Ref: ViiV Healthcare | Image: ViiV Healthcare
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
